Steve Offord1, Jay Lin, Dario Mirski, Bruce Wong. 1. Otsuka America Pharmaceutical, Inc., 1 University Square Drive, Princeton, New Jersey 08540, USA. Steve.Offord@otsuka-us.com
Abstract
INTRODUCTION: To quantify early nonadherence to antipsychotic medications in patients with schizophrenia and its impact on short-term antipsychotic adherence, healthcare utilization, and costs. METHODS: Patients who initiated oral antipsychotic treatment between January 1, 2006 to September 30, 2009 were identified from the MarketScan® Commercial Claims and Encounters (CCE) database (Truven Health Analytics, Ann Arbor, Michigan, USA). Patients were required to have a diagnosis of schizophrenia determined by the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code 295.x, be 13-65 years of age, and have ≥ 12 months of continuous coverage prior to and after (follow-up) the earliest antipsychotic usage (index event). Medication discontinuation was defined as a gap of 30 days in available therapy; early nonadherence was defined as having the gap 90 days from the index event. During the follow-up period, medication adherence was estimated with quarterly medication possession ratios (MPR), and all-cause and schizophrenia-related healthcare resource utilization and costs were determined. RESULTS: The mean time to discontinuation (TTD) was 39.5 ± 20.1 days for early nonadherence patients (n = 873) and 250.7 ± 103.3 days for patients who were adherent early (n = 589). Early nonadherence resulted in more hospitalizations (0.57 vs. 0.38; P = 0.0006) with longer length of stay (LOS, 5.0 vs. 3.0 days; P = 0.0013) and higher costs ($5,850 vs. $4,211; P = 0.0244); schizophrenia-related hospitalizations, LOS, and costs were also greater. Patients that were adherent used more schizophrenia-related medications (10.4 vs. 4.7; P < 0.0001), increasing pharmacy costs ($3,684 vs. $1,549; P < 0.0001). Early nonadherence was correlated with lower drug adherence at each quarter of the follow-up period. CONCLUSION: Approximately 60% of patients with schizophrenia are nonadherent to antipsychotic medication early in treatment and are less likely to be adherent later. Early nonadherence resulted in more all-cause and schizophrenia-related hospitalizations with a greater LOS and cost of care.
INTRODUCTION: To quantify early nonadherence to antipsychotic medications in patients with schizophrenia and its impact on short-term antipsychotic adherence, healthcare utilization, and costs. METHODS:Patients who initiated oral antipsychotic treatment between January 1, 2006 to September 30, 2009 were identified from the MarketScan® Commercial Claims and Encounters (CCE) database (Truven Health Analytics, Ann Arbor, Michigan, USA). Patients were required to have a diagnosis of schizophrenia determined by the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code 295.x, be 13-65 years of age, and have ≥ 12 months of continuous coverage prior to and after (follow-up) the earliest antipsychotic usage (index event). Medication discontinuation was defined as a gap of 30 days in available therapy; early nonadherence was defined as having the gap 90 days from the index event. During the follow-up period, medication adherence was estimated with quarterly medication possession ratios (MPR), and all-cause and schizophrenia-related healthcare resource utilization and costs were determined. RESULTS: The mean time to discontinuation (TTD) was 39.5 ± 20.1 days for early nonadherence patients (n = 873) and 250.7 ± 103.3 days for patients who were adherent early (n = 589). Early nonadherence resulted in more hospitalizations (0.57 vs. 0.38; P = 0.0006) with longer length of stay (LOS, 5.0 vs. 3.0 days; P = 0.0013) and higher costs ($5,850 vs. $4,211; P = 0.0244); schizophrenia-related hospitalizations, LOS, and costs were also greater. Patients that were adherent used more schizophrenia-related medications (10.4 vs. 4.7; P < 0.0001), increasing pharmacy costs ($3,684 vs. $1,549; P < 0.0001). Early nonadherence was correlated with lower drug adherence at each quarter of the follow-up period. CONCLUSION: Approximately 60% of patients with schizophrenia are nonadherent to antipsychotic medication early in treatment and are less likely to be adherent later. Early nonadherence resulted in more all-cause and schizophrenia-related hospitalizations with a greater LOS and cost of care.
Authors: Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux Journal: CNS Drugs Date: 2015-08 Impact factor: 5.749
Authors: Julie Kreyenbuhl; Elizabeth J Record; Seth Himelhoch; Melanie Charlotte; Jessica Palmer-Bacon; Lisa B Dixon; Deborah R Medoff; Lan Li Journal: Clin Schizophr Relat Psychoses Date: 2016-07-25
Authors: Nursen Yalcin-Siedentopf; Fabienne Wartelsteiner; Alexandra Kaufmann; Falko Biedermann; Monika Edlinger; Georg Kemmler; Maria A Rettenbacher; Christian G Widschwendter; Gerald Zernig; W Wolfgang Fleischhacker; Alex Hofer Journal: Int J Neuropsychopharmacol Date: 2014-12-07 Impact factor: 5.176
Authors: Sudeep Karve; Michael Markowitz; Dong-Jing Fu; Jean-Pierre Lindenmayer; Chi-Chuan Wang; Sean D Candrilli; Larry Alphs Journal: Appl Health Econ Health Policy Date: 2014-06 Impact factor: 2.561
Authors: John M Kane; Raymond Sanchez; Joan Zhao; Anna R Duca; Brian R Johnson; Robert D McQuade; Anna Eramo; Ross A Baker; Timothy Peters-Strickland Journal: J Med Econ Date: 2013-05-28 Impact factor: 2.448